Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2016

View Archived Issues

Merus signs agreement for GlymaxX enhancement technology

MiNA Therapeutics initiates phase I trial of MTL-CEBPA in advanced liver cancer

Achaogen awarded funding for phase III EPIC study

FDA awards orphan drug designation to Escend's ES-3000 for CML

Kite Pharma enters research collaboration with Cell Design Labs

Arrien Pharmaceuticals begins phase I trials of ARN-6039

Anti-PD-1 MAb REGN-2810 well tolerated in first-in-human study in patients with solid tumors

Animal model studies give insight into mechanisms of disease

Afinitor receives approval in the E.U. for the treatment of advanced GI and lung NET

Foundation Medicine and AstraZeneca partner to develop companion diagnostic assay for Lynparza

GlaxoSmithKline patents SIRT1 activators

State University of New Jersey discloses compounds for metabolic diseases and cancer

Johns Hopkins University reports new drug conjugates

FORGE Life Science announces antiviral compounds

Ganymed presents promising preclinical data for its novel ADCs as treatments against cancer

Phase II/III trial of VLA-43 does not confirm previously seen positive vaccine effect

Array BioPharma, Pierre Fabre and Merck KGaA collaborate on BEACON CRC trial

Angiogenesis inhibitor X-82 combined with everolimus in patients with solid tumors

sDPP-IV levels associated with all-cause death in patients with PAD

The Global Health Innovative Technology reports new funding partnerships

Phase III study of dupilumab in moderate to severe atopic dermatitis meets key endpoints

Phase III trial of Actemra in giant cell arteritis meets key endpoints

Interim results show Frontier's phase III trial of albuvirtide for HIV meets primary objective

Vedanta raises new financing to advance microbiome therapeutics

IL-27p28 gene polymorphisms may be correlated with insulin resistance and artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...